Sustained clinical remission rates with 2-years of benralizumab treatment among SEA patients in XALOC-1 trial

Dupilumab demonstrates significant efficacy and safety outcomes for patients with COPD and type 2 inflammation: The phase 3 BOREAS trial

Molnupiravir and nirmatrelvir-ritonavir remain efficacious for unvaccinated COVID-19 patients with chronic respiratory diseases in real-world settings

Redefining the lung function parameters in assessing clinical remission of severe asthma with mepolizumab treatment: A post-hoc analysis of the REDES study

Multi-database cohort study demonstrated an increased risk of severe CV events after COPD exacerbations

Efficacy of autologous blood patch therapy in managing persistent air leak and secondary spontaneous pneumothorax

Comprehending the mechanisms of COPD-related metabolic alterations paves the way for more effective treatments

Addition of PRN ICS/formoterol treatment approach for patients with mild asthma: Amendments for the ERS guidelines